SG158145A1 - Vaccines against chlamydial infection - Google Patents

Vaccines against chlamydial infection

Info

Publication number
SG158145A1
SG158145A1 SG200908390-8A SG2009083908A SG158145A1 SG 158145 A1 SG158145 A1 SG 158145A1 SG 2009083908 A SG2009083908 A SG 2009083908A SG 158145 A1 SG158145 A1 SG 158145A1
Authority
SG
Singapore
Prior art keywords
vaccines against
chlamydial infection
against chlamydial
proteins
polynucleotides
Prior art date
Application number
SG200908390-8A
Other languages
English (en)
Inventor
Brenda Barth
Ajay Bhatia
Mark Alderson
Jean-Francois L Maisonneuve
Yves Lobet
Florence Bernadette Nozay
Martine Marchand
Pascal Mettens
Yasir A Skeiky
Peter Probst
Original Assignee
Glaxosmithkline Biolog Sa
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Corixa Corp filed Critical Glaxosmithkline Biolog Sa
Publication of SG158145A1 publication Critical patent/SG158145A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200908390-8A 2005-03-31 2006-03-24 Vaccines against chlamydial infection SG158145A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66733105P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
SG158145A1 true SG158145A1 (en) 2010-01-29

Family

ID=36646973

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200908390-8A SG158145A1 (en) 2005-03-31 2006-03-24 Vaccines against chlamydial infection

Country Status (16)

Country Link
US (1) US20090022755A1 (pt)
EP (5) EP1868641A2 (pt)
JP (2) JP2008534594A (pt)
KR (1) KR20070121814A (pt)
CN (2) CN103372206A (pt)
AU (1) AU2006229968A1 (pt)
BR (1) BRPI0609547A2 (pt)
CA (1) CA2602637A1 (pt)
EA (2) EA014527B1 (pt)
IL (1) IL186264A0 (pt)
MA (1) MA30250B1 (pt)
MX (1) MX2007012108A (pt)
NO (1) NO20075069L (pt)
SG (1) SG158145A1 (pt)
UA (1) UA97943C2 (pt)
WO (1) WO2006104890A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
JP2008544745A (ja) * 2005-05-12 2008-12-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓのための免疫原性組成物
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
EA021391B1 (ru) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
WO2008156729A2 (en) * 2007-06-14 2008-12-24 Emergent Product Development Gaithersburg Inc. Vaccines against chlamydia infection
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
AU2010207828B2 (en) * 2009-01-29 2016-07-14 British Columbia Cancer Agency Branch Compositions comprising Chlamydia antigens
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
ES2788728T3 (es) 2010-05-28 2020-10-22 Spixia Biotechnology Ab Antígeno de la MOMP quimérica, método y uso
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
KR101275263B1 (ko) * 2011-04-01 2013-06-14 서울대학교산학협력단 조류 병원성 대장균 특이 박테리오파지 및 이를 포함하는 항균 조성물
US8785145B2 (en) 2011-08-11 2014-07-22 Ingen Biosciences Method for diagnosing gram-negative infections
EP2586789A1 (en) * 2011-08-11 2013-05-01 InGen Biosciences Method for diagnosing gram-negative infections
JP2015501293A (ja) * 2011-09-30 2015-01-15 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア クラミジア抗原組成物およびその使用
EP2854777B1 (en) * 2012-05-29 2016-12-28 The Research Foundation for the State University of New York Combined therapy and prophylaxis for genital tract infections
CN104812406A (zh) * 2012-08-08 2015-07-29 英属哥伦比亚大学 衣原体抗原组合物及其用途
WO2015106345A1 (en) 2014-01-16 2015-07-23 Mcmaster University Type iii secretion injectisome proteins for treatment and prevention of chlamydial infections
US10675339B2 (en) * 2014-11-21 2020-06-09 Merck Sharp & Dohme Corp. Recombinant expression of Chlamydia MOMP antigen
AU2016219379B2 (en) 2015-02-10 2020-11-26 Ohio State Innovation Foundation Chlamydia-activated B cell platforms and methods thereof
JP7086000B2 (ja) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション 体液性親和性の加速に関する方法及び組成物
RU2676768C2 (ru) * 2016-05-12 2019-01-11 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Противохламидийная вакцина и способ ее получения
US20210106668A1 (en) * 2017-03-23 2021-04-15 Ohio State Innovation Foundation Recombinant chlamydia-activated b cell platforms and methods of use thereof
CN108623657B (zh) * 2018-05-11 2021-02-12 苏州大学 多肽、重组dna分子、重组载体、外泌体及其应用
KR20230135620A (ko) * 2021-01-29 2023-09-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 클라미디아 트라코마티스 항원 폴리펩타이드 및 백신목적을 위한 이의 용도

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
WO1989006280A1 (en) 1988-01-04 1989-07-13 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
DK0553288T3 (da) 1990-10-18 1997-12-29 Cellpro Inc Apparat og fremgangsmåde til udskillelse af partikler ved brug af en eftergivende beholder
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0877085A1 (en) 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
DK0641192T3 (da) 1992-05-18 1998-03-02 Minnesota Mining & Mfg Anordning til transmucosal lægemiddelafgivelse
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2220530A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. Improved method for obtaining full-length cdna sequences
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
WO1999028475A2 (en) 1997-11-28 1999-06-10 Genset Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PT1584685E (pt) 1998-02-05 2011-06-17 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
JP2002511423A (ja) 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
WO2000034483A2 (en) * 1998-12-08 2000-06-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6166177A (en) 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
DE60133190T2 (de) * 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002079244A2 (en) * 2001-03-30 2002-10-10 University Of Manitoba Chlamydial protease-like activity factor responsible for degradation of host transcription factor
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US6770753B2 (en) * 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
NZ546711A (en) * 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
MXPA05013260A (es) * 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease

Also Published As

Publication number Publication date
BRPI0609547A2 (pt) 2011-10-18
EP1868641A2 (en) 2007-12-26
EP2392348A2 (en) 2011-12-07
EP2392348A3 (en) 2012-01-18
UA97943C2 (ru) 2012-04-10
WO2006104890A3 (en) 2007-03-29
EP2392347A2 (en) 2011-12-07
EP2392349A2 (en) 2011-12-07
CA2602637A1 (en) 2006-10-05
JP2012180367A (ja) 2012-09-20
WO2006104890A2 (en) 2006-10-05
AU2006229968A1 (en) 2006-10-05
MX2007012108A (es) 2007-12-05
EA200701825A1 (ru) 2008-04-28
KR20070121814A (ko) 2007-12-27
EP2392349A3 (en) 2012-01-18
EA201001322A1 (ru) 2011-02-28
CN103372206A (zh) 2013-10-30
EA014527B1 (ru) 2010-12-30
MA30250B1 (fr) 2009-03-02
EP2386314A1 (en) 2011-11-16
CN101184504A (zh) 2008-05-21
EP2392347A3 (en) 2012-01-18
JP2008534594A (ja) 2008-08-28
US20090022755A1 (en) 2009-01-22
NO20075069L (no) 2007-12-27
IL186264A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
SG158145A1 (en) Vaccines against chlamydial infection
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
HK1113085A1 (en) Compounds, compositions and methods for the treatment of poxvirus infections
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
TW200637522A (en) Skin treatment articles and methods
TW200740458A (en) Vaccination against dengue virus infection
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
WO2009118662A3 (en) Methods and compositions for treating bone loss
GB0710529D0 (en) Vaccine
EP2348039A3 (en) Cyclic antimicrobial peptides
EP2192901A4 (en) CHEMICAL AGENTS, COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND RELATED DISEASES
CL2007003332A1 (es) Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2007028151A3 (en) Surgical devices and related methods thereof
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2008085549A3 (en) Compositions and methods for stimulation of lung innate immunity
WO2008097364A3 (en) Use of oritavancin for prevention and treatment of anthrax
WO2008105826A3 (en) Compositions compromising lysostaphin variants and methods of using the same
MX2007011381A (es) Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion.
IL194353A0 (en) Lysobactin amides
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EP1959999A4 (en) POLYNUCLEOTIDES AND POLYPEPTIDE OF HUMAN KV1.3, COMPOSITIONS AND METHOD OF ADMINISTRATION THEREFOR
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases